Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan

ObjectivesData on the safety and efficacy of cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer (CRPC) are limited. We report the safety (adverse drug reactions [ADRs]) and efficacy (overall survival [OS], time to treatment failure [TTF], and prostate-specific antigen [PSA] response rates) in patients aged <80 or ≥80 years treated with cabazitaxel for CRPC in clinical practice.Materials and methodsWe performed post-hoc subgroup analyses of a Japanese post-marketing surveillance study involving 662 patients with CRPC treated with cabazitaxel between September 2014 and June 2016.ResultsIn patients aged <80 (n = 610) and ≥80 years (n = 49), median PSA at baseline was 168.7 and 109.0 ng/mL, and 86.7% and 83.7% of patients were previously treated with enzalutamide and/or abiraterone. ADRs (all grade) occurred in 77.2% and 79.6% of patients aged <80 and ≥80 years, with grade three/worse ADRs in 61.8% and 63.3% of patients. Hematologic toxicities were the most common grade three/worse ADRs, including neutropenia, febrile neutropenia, and anemia in both subgroups. No specific ADRs were observed in patients aged ≥80 years. The PSA response and median OS and TTF were 28.3%, 292 days, and 116 days in patients aged ≥80 years, and 29.7%, 319 days, and 125 days in patients aged <80 years.ConclusionCabazitaxel could be a treatment option for CRPC in patients aged ≥80 years based on its safety and efficacy profiles. This is the first report to investigate the safety and efficacy of cabazitaxel in patients aged ≥80 years with CRPC.     

儿童期创伤应对方式自动思维与大学生抑郁特质间的关系

目的探讨儿童期创伤与抑郁特质之间的中介和调节机制,为开展相关研究和干预提供参考。方法2017-2018年采用整群抽样的方法,抽取湖南某高校大一年级2 786名学生完成儿童期创伤问卷、状态特质抑郁问卷、自动思维问卷和特质应对方式问卷的调查。结果儿童期创伤、自动思维和消极应对对抑郁特质起正向的预测作用,积极应对对抑郁特质起负向的预测作用(β值分别为0.12,0.43,0.14,-0.33,P值均<0.05)。自动思维中介儿童期创伤与抑郁特质之间的关系(Bootstrapping法的95%CI为0.03~0.06)。消极应对分别调节了儿童期创伤与自动思维和儿童期创伤与抑郁特质之间的关系(P值均<0.05)。结论儿童期创伤影响抑郁特质,其关系受到应对方式和自动思维的影响。     

Postoperative Course of Serum Albumin Levels and Organ Dysfunction After Liver Transplantation

Background and aimsPostoperative hypoalbuminemia, especially following liver transplantation, can lead to adverse multisystem effects and even death. We investigated the relationship between postoperative albumin levels and organ failure (assessed using Sequential Organ Failure Assessment [SOFA] scores).MethodsSixty liver transplant recipients admitted to the intensive care unit (ICU) from 2012 to 2015 were retrospectively divided into 2 groups: lower albumin (LA) (n=28) and higher albumin (HA) (n=32), using whether serum albumin level fell below 3.0 g/dL during the first postoperative week as the stratifying factor. The SOFA scores (primary endpoint) and associated complications (ascites amount, rejection, re-intubation, abdominal re-operation, thrombosis), additional treatment (dialysis, pleural effusion drainage), and duration of ICU stay (secondary endpoints) of the 2 groups were compared.ResultsAverage serum albumin levels were significantly different between HA and LA groups (3.6 [3.4–3.8] vs 3.1 [2.9–3.3], respectively, P < .05), although the amounts of albumin infused in the 2 groups during the first postoperative week were not different (HA vs LA: 42 [30–71] vs 40 [30–58], respectively, P = .37). Mean daily SOFA scores were not significantly different between the HA and LA groups (8.3 [6.6–9.0] vs 7.2 [6.3–8.6], P = .73), although the HA group had lower mean cardiovascular SOFA sub-scores than the LA group (0.1 [0–0.4] vs 0.4 [0–1.3], P = .032). There were no significant differences between the groups with regard to complication rates and duration of ICU and hospital stays.ConclusionsSerum albumin level might not influence cumulative organ function, but it decreases the amount of hemodynamic support required in liver transplant recipients.     

Dual wavelength 5-aminolevulinic acid photodynamic therapy using a novel flexible light-emitting diode unit

Background

Photosensitizers used for photodynamic therapy (PDT) to treat dermatologic disease are metabolized into mainly protoporphyrin IX (PpIX), which has five absorption wavelength peaks: 410?nm, 510?nm, 545?nm, 580?nm, and 630?nm. Although only red light around 635?nm and blue light around 400?nm are used as light sources for PDT, the efficiency of PDT might be improved by using multiple wavelengths, including those that correspond to the other absorption peaks of PpIX. Furthermore, because the target disease often occurs on the face, a flexible-type light-source unit that can be fitted to the lesion without unnecessarily exposing the mucous membranes, e.g., the eyes, nostrils, and mouth, is preferred.